A randomized, placebo-controlled clinical trial examining the efficacy of Fecal Microbiota Transplantation (FMT) and subsequent dietary fiber in patients with moderate ulcerative colitis (MINDFUL)
一项随机、安慰剂对照临床试验,检验粪便微生物群移植 (FMT) 和随后的膳食纤维对中度溃疡性结肠炎 (MINDFUL) 患者的疗效
基本信息
- 批准号:10631895
- 负责人:
- 金额:$ 33.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-06 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:AffectAmericanAnimal ModelBacteriaBiologicalCell physiologyCellsClinicalClinical ResearchColitisComplexComputer softwareDataDietDietary FiberDietary InterventionDietary SupplementationEngraftmentEnzymesFiberImmuneImmunityImmunologicsInflammatory Bowel DiseasesInterventionIntestinesMedicalMetagenomicsMicrobeMucositisNutrientOutcomeParticipantPatientsPharmaceutical PreparationsPlacebosPolysaccharidesPsylliumRandomizedRandomized, Controlled TrialsRefractory DiseaseResearchResearch InfrastructureResourcesRoleShapesSourceSupplementationTestingUlcerative ColitisVolatile Fatty AcidsWorkbioinformatics pipelinechronic inflammatory diseaseclinical efficacyclinical infrastructureclinical remissiondesigndouble-blind placebo controlled trialeffective therapyefficacy evaluationfecal transplantationfollow-upgut inflammationgut microbiomehealingimprovedinclusion criteriameetingsmetabolomicsmicrobialmicrobiomemicrobiome analysismicrobiotanovelnovel strategiesnovel therapeutic interventionopen labelpre-clinical researchprebioticsprimary endpointrandomized placebo-controlled clinical trialresponsesecondary endpoint
项目摘要
Ulcerative colitis (UC) is a chronic inflammatory disease of the intestine affecting over 1 million Americans.
Despite advances in medical therapies, nearly half of the patients requiring biologic medications will develop
medically refractory disease. As such, there is an urgent need for new treatment approaches for UC.
Emerging data from several randomized controlled trials (RCTs) suggest that fecal microbiota transplantation
(FMT) is safe and effective for the treatment of UC. Although extensive pre-clinical research showing a central
role for the gut microbiome in regulating animal models of colitis support these encouraging clinical findings,
variability in the efficacy of FMT for UC has limited the clinical impact. Research from our own group and
others has shown that the composition of the donor microbiome is associated with clinical response. Our
preliminary data extend these findings with strain level characterization showing that a core transferable
microbiota correlates with clinical response to FMT in UC. A detailed understanding of the mechanisms that
promote the transfer and engraftment of these beneficial bacteria is needed to enhance the clinical efficacy of
FMT for UC. Diet is a critical regulator of the intestinal microbiome and its subsequent impact on intestinal
inflammation, but the effect of diet and/or prebiotic supplementation on microbial engraftment and clinical
outcome following FMT has never been tested. It is, therefore, a critical need to assess the role for dietary
interventions in shaping the microbiome and clinical outcomes of FMT for UC. This proposal will evaluate the
fundamental hypothesis that dietary fiber supplementation can improve the clinical efficacy of FMT by shaping
microbial engraftment and function of specific transferable microbes. We propose the following aims to
evaluate this hypothesis: (i) to test the potential impact of fiber to improve clinical outcomes of FMT for UC with
a randomized, double-blind, placebo-controlled trial of FMT with or without open-label dietary fiber
supplementation for the treatment of mild to moderate UC; (ii) to define the impact of fiber supplementation on
microbial engraftment and immune cell function after FMT in patients with UC. If successful, our study will offer
critical support for the role of dietary fiber in shaping the outcome of FMT. Furthermore, our microbiome,
metabolomic, and immunologic characterization will provide key mechanistic analysis to support the design of
larger follow-up clinical studies. Given the feasibility and practicality of this intervention, results from this work
have the potential to transform FMT for UC as well as other indications.
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
randy s longman其他文献
randy s longman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('randy s longman', 18)}}的其他基金
A randomized, placebo-controlled clinical trial examining the efficacy of Fecal Microbiota Transplantation (FMT) and subsequent dietary fiber in patients with moderate ulcerative colitis (MINDFUL)
一项随机、安慰剂对照临床试验,检验粪便微生物群移植 (FMT) 和随后的膳食纤维对中度溃疡性结肠炎 (MINDFUL) 患者的疗效
- 批准号:
10183772 - 财政年份:2021
- 资助金额:
$ 33.9万 - 项目类别:
A randomized, placebo-controlled clinical trial examining the efficacy of Fecal Microbiota Transplantation (FMT) and subsequent dietary fiber in patients with moderate ulcerative colitis (MINDFUL)
一项随机、安慰剂对照临床试验,检验粪便微生物群移植 (FMT) 和随后的膳食纤维对中度溃疡性结肠炎 (MINDFUL) 患者的疗效
- 批准号:
10385825 - 财政年份:2021
- 资助金额:
$ 33.9万 - 项目类别:
TL1A Regulation of Group 3 Innate Lymphoid Cells in Colitis
TL1A 对结肠炎中第 3 组先天淋巴细胞的调节
- 批准号:
10357907 - 财政年份:2020
- 资助金额:
$ 33.9万 - 项目类别:
TL1A Regulation of Group 3 Innate Lymphoid Cells in Colitis
TL1A 对结肠炎中第 3 组先天淋巴细胞的调节
- 批准号:
9886697 - 财政年份:2020
- 资助金额:
$ 33.9万 - 项目类别:
TL1A Regulation of Group 3 Innate Lymphoid Cells in Colitis
TL1A 对结肠炎中第 3 组先天淋巴细胞的调节
- 批准号:
10589869 - 财政年份:2020
- 资助金额:
$ 33.9万 - 项目类别:
Multidisciplinary Research Training in Gastroenterology and Hepatology
胃肠病学和肝病学多学科研究培训
- 批准号:
10400886 - 财政年份:2019
- 资助金额:
$ 33.9万 - 项目类别:
Multidisciplinary Research Training in Gastroenterology and Hepatology
胃肠病学和肝病学多学科研究培训
- 批准号:
10612780 - 财政年份:2019
- 资助金额:
$ 33.9万 - 项目类别:
Multidisciplinary Research Training in Gastroenterology and Hepatology
胃肠病学和肝病学多学科研究培训
- 批准号:
10632345 - 财政年份:2019
- 资助金额:
$ 33.9万 - 项目类别:
Multidisciplinary Research Training in Gastroenterology and Hepatology
胃肠病学和肝病学多学科研究培训
- 批准号:
10621459 - 财政年份:2019
- 资助金额:
$ 33.9万 - 项目类别:
Multidisciplinary Research Training in Gastroenterology and Hepatology
胃肠病学和肝病学多学科研究培训
- 批准号:
10133062 - 财政年份:2019
- 资助金额:
$ 33.9万 - 项目类别:
相似海外基金
Impact of Mitochondrial Lipidomic Dynamics and its Interaction with APOE Isoforms on Brain Aging and Alzheimers Disease
线粒体脂质组动力学及其与 APOE 亚型的相互作用对脑衰老和阿尔茨海默病的影响
- 批准号:
10645610 - 财政年份:2023
- 资助金额:
$ 33.9万 - 项目类别:
Validation of the joint-homing and drug delivery attributes of novel peptides in a mouse arthritis model
在小鼠关节炎模型中验证新型肽的关节归巢和药物递送特性
- 批准号:
10589192 - 财政年份:2023
- 资助金额:
$ 33.9万 - 项目类别:
Synergistically Target Mitochondria for Heart Failure Treatment
协同靶向线粒体治疗心力衰竭
- 批准号:
10584938 - 财政年份:2023
- 资助金额:
$ 33.9万 - 项目类别: